According to a recent LinkedIn post from ABM Respiratory Care, the company is showcasing its BiWaze platform of airway clearance systems at the ATS 2026 conference, inviting attendees to Booth 1803 to see the technology demonstrated. The post highlights BiWaze Clear, which is described as combining lung expansion, high-frequency oscillation, and nebulization in a single therapy.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The post also describes BiWaze Cough, noting features such as a live waveform viewer to support titration and synchrony capabilities designed to align therapy with the patient’s inspiratory and expiratory phases. By emphasizing engagement with clinicians, researchers, and respiratory care leaders at ATS, the post suggests ABM is using the conference as a strategic channel to build clinical awareness, gather feedback, and potentially drive future adoption of its airway clearance solutions.
For investors, the presence at a major respiratory conference may indicate continued investment in clinical marketing and product differentiation within the pulmonary care and airway clearance segments. If the BiWaze platform gains traction with key opinion leaders and healthcare institutions, it could support longer-term revenue growth prospects, though near-term financial impact would depend on conversion of this visibility into commercial contracts and reimbursement acceptance.